JVJeffrey M. Vinocur

Jeffrey M. Vinocur

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jeffrey M. Vinocur has a total of 313 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Efficacy of glucagon-like-peptide-1 agonists for weight loss in adults with CHD

    by Prinston Varghese, Robert W. Elder, Jeffrey M. Vinocur, Erica S. Spatz, Veronika Shabanova, Sarah McCollum, Morgan Harper, Tony Pastor

    Background: Glucagon-like-peptide-1 (GLP-1) agonists are beneficial for glycaemic control, weight loss, and cardiovascular health. Because GLP-1 agonists may be a useful tool in the management of obesity in patients with congenital heart disease (CHD), we examined whether GLP-1 agonists are effective and safe for weight loss in adults with congenital heart disease (ACHD) and explored the effects of sex and CHD complexity. Methods: We conducted a retrospective cohort study of ACHD patients who were prescribed a GLP-1 agonist from 1/1/2022–3/31/2024 at Yale New Haven Hospital. Patients were subdivided by CHD anatomic complexity. The primary outcome was the change in weight over time. Side effects were explored as a secondary outcome. Results: The moderate complexity ACHD group had the fastest weight loss during both the first 6 months and 12 months of treatment, but was comparable to the other two ACHD complexities in the full period of follow-up. Patients in the simple and great complexity groups required 12 months of treatment to reach meaningful weight loss. Females had a faster rate of weight loss compared to males across all ACHD complexity levels. The most common side effects reported were gastrointestinal, such as nausea, acid reflux, and diarrhoea. Conclusion: This study provides evidence that GLP-1 agonists are effective for weight loss in ACHD patients, with the greatest weight loss in females and patients with moderate ACHD complexity. Moreover, GLP-1 agonists in the ACHD population have a reasonable side effect profile that is typical for these agents.

  • Risk of late sudden death after surgery for congenital heart disease

    by Joseph S. Needleman, Robert D. Whitehill, J’nEka S. Claxton, Courtney McCracken, Rachel Zmora, Jeffrey M. Vinocur, Matthew E. Oster, Lazaros Kochilas

    Background: Sudden cardiac death is a significant concern among patients with congenital heart disease (CHD). We assessed the risk of remote sudden cardiac death after congenital heart surgery.Methods: Patients undergoing congenital heart surgery before 21 years of age between 1982 and 2003 in the Pediatric Cardiac Care Consortium registry were linked to National Death Index data through 2019. Sudden cardiac death was defined as death associated with a cardiac arrest or ventricular fibrillation diagnosis code. Standardised mortality ratios relative to the general population were calculated using Centers for Disease Control and Prevention data.Results: Among 30,566 patients discharged after their initial surgery, 2,718 deaths occurred over a median period of 23 years (IQR 19–27). Of 463 (17%) sudden cardiac deaths, the median age was 1.7 years (IQR 0.5–16.5). The mean incidence was 7 per 10,000 person-years (95% CI: 0.64–0.77), ranging from 2.7 for left-to-right shunt lesions to 37 for single-ventricle physiology. Cardiac comorbidities including heart failure (13.6%) and arrhythmias (7.1%) were more frequent among sudden cardiac death patients. Standard mortality ratios for sudden cardiac death were elevated across all CHD types, ranging from 8.0 (95% CI: 6.3–9.6) for left-to-right shunts to 107.7 (95% CI: 88.9–126.5) for single-ventricle physiology.Conclusion: Sudden cardiac death risk is higher post-congenital heart surgery compared to the general population. Even patients with mild CHD are at risk, highlighting the need for long-term follow-up for all patients. Heart failure and arrhythmia prevalence suggest potential therapeutic targets to reduce sudden cardiac death risk.


  • Open Access

    Reduced kinase function in two ultra‐rare TNNI3K variants in families with congenital junctional ectopic tachycardia

    by Caroline Pham, Tamara T. Koopmann, Jeffrey M. Vinocur, Nico A. Blom, Vivian Nogueira Silbiger, Kirti Mittal, Marianne Bootsma, Kaylin C. A. Palm, Sally‐Ann B. Clur, Daniela Q. C. M. Barge‐Schaapveld, et al.

    Genetic missense variants in TNNI3K, encoding troponin‐I interacting kinase, have been associated with dilated cardiomyopathy (DCM) and observed in families with supraventricular tachycardias (SVT). Previously, a family harboring the TNNI3K‐c.1615A > G (p.Thr539Ala) variant presented with congenital junctional ectopic tachycardia (CJET), an arrhythmia that arises from the atrioventricular (AV) node and His bundle. However, this was a relatively small four‐generational family with limited genetic testing (N = 3). We here describe a multigenerational family with CJET harboring a novel ultra‐rare TNNI3K variant: TNNI3K‐c.1729C > T (p.Leu577Phe). Of all 18 variant carriers, 13 individuals presented with CJET, resulting in a genetic penetrance of 72%. In addition, CJET is reported in another small family harboring TNNI3K‐c.2225C > T (p.Pro742Leu). Similar to the previously published CJET family, both TNNI3K variants demonstrate a substantial reduction of kinase activity. Our study contributes novel evidence supporting the involvement of TNNI3K genetic variants as significant contributors to CJET, shedding light on potential mechanisms underlying this cardiac arrhythmia.


  • Lyme Carditis in the Pediatric Population

    by Cheyenne M. Beach, Jeffrey M. Vinocur

  • Open Access

    Clinical presentation of calmodulin mutations: the International Calmodulinopathy Registry

    by Lia Crotti, Carla Spazzolini, Mette Nyegaard, Michael T Overgaard, Maria-Christina Kotta, Federica Dagradi, Luca Sala, Takeshi Aiba, Mark D Ayers, Anwar Baban, et al.

    Calmodulinopathy due to mutations in any of the three CALM genes (CALM1–3) causes life-threatening arrhythmia syndromes, especially in young individuals. The International Calmodulinopathy Registry (ICalmR) aims to define and link the increasing complexity of the clinical presentation to the underlying molecular mechanisms. The ICalmR is an international, collaborative, observational study, assembling and analysing clinical and genetic data on CALM-positive patients. The ICalmR has enrolled 140 subjects (median age 10.8 years [interquartile range 5–19]), 97 index cases and 43 family members. CALM-LQTS and CALM-CPVT are the prevalent phenotypes. Primary neurological manifestations, unrelated to post-anoxic sequelae, manifested in 20 patients. Calmodulinopathy remains associated with a high arrhythmic event rate (symptomatic patients, n = 103, 74%). However, compared with the original 2019 cohort, there was a reduced frequency and severity of all cardiac events (61% vs. 85%; P = .001) and sudden death (9% vs. 27%; P = .008). Data on therapy do not allow definitive recommendations. Cardiac structural abnormalities, either cardiomyopathy or congenital heart defects, are present in 30% of patients, mainly CALM-LQTS, and lethal cases of heart failure have occurred. The number of familial cases and of families with strikingly different phenotypes is increasing. Calmodulinopathy has pleiotropic presentations, from channelopathy to syndromic forms. Clinical severity ranges from the early onset of life-threatening arrhythmias to the absence of symptoms, and the percentage of milder and familial forms is increasing. There are no hard data to guide therapy, and current management includes pharmacological and surgical antiadrenergic interventions with sodium channel blockers often accompanied by an implantable cardioverter–defibrillator. Number and percentages of patients with CALM variants and LQTS, CPVT, LQTS/CPVT overlap, IVF, UD, and SCD are reported in the upper left part of the graphical abstract together with two examples of LQTS and CPVT electrocardiograms. In the upper right part, it is shown a graphical representation of the reduction of all cardiac events and SCD between the original cohort (up to 2019) and the cases enrolled between 2019 and 2023. In the lower part, it is reported the number or percentage of CALM patients with cardiomyopathies, congenital heart defects, and neurological features. CALM, calmodulin; LQTS, long QT syndrome; CPVT, catecholaminergic polymorphic ventricular tachycardia; ICD, implantable cardioverter–defibrillator; IVF, idiopathic ventricular fibrillation; UD, uncertain diagnosis; SCD, sudden cardiac death.


  • An unusual cause of repolarization abnormality after congenital heart surgery: A case report

    by Nicholas V. Barresi, Brian S. Marcus, Cheyenne M. Beach, Jeffrey M. Vinocur

  • Open Access

    Fortuitous Left Bundle Branch Area Pacing in a Small Child

    by Jeffrey M. Vinocur